Cabaletta Bio (CABA) Stock Price

Cabaletta Bio Price

NASDAQ·CLOSED
2.97USD-0.14 (-4.60 %)
Market closed

Analysts set a median price target of 14.28 USD, implying 380.0% above the current price. Of 16 analysts, 13 rate the stock a buy — an overall Buy consensus. The stock trades about 124% above its 52-week low.

Cabaletta Bio stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Cabaletta Bio over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Cabaletta Bio stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Cabaletta Bio's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Cabaletta Bio Stock Price History
DateCabaletta Bio Price
7/10/20262.97 USD
7/9/20263.12 USD
7/8/20263.06 USD
7/7/20263.10 USD
7/6/20263.26 USD
7/2/20263.19 USD
7/1/20262.99 USD
6/30/20263.11 USD
6/29/20263.11 USD
6/26/20263.04 USD
6/25/20262.92 USD
6/24/20263.03 USD
6/23/20263.02 USD
6/22/20262.95 USD
6/18/20262.84 USD
6/17/20262.84 USD
6/16/20262.80 USD
6/15/20263.01 USD
6/12/20263.01 USD
6/11/20263.01 USD
6/10/20263.33 USD
6/9/20263.22 USD
6/8/20263.20 USD
6/5/20263.25 USD
6/4/20263.51 USD
6/3/20263.58 USD
6/2/20263.68 USD
6/1/20263.67 USD
5/29/20263.78 USD
5/28/20263.77 USD
5/27/20263.83 USD
5/26/20263.72 USD
5/22/20263.65 USD
5/21/20263.69 USD
5/20/20263.44 USD
5/19/20263.27 USD
5/18/20263.29 USD
5/15/20263.31 USD
5/14/20263.61 USD
5/13/20263.59 USD
5/12/20263.63 USD
5/11/20263.82 USD
5/8/20263.88 USD
5/7/20264.00 USD
5/6/20263.73 USD
5/5/20264.15 USD
5/4/20263.83 USD
5/1/20262.94 USD
4/30/20262.99 USD
4/29/20262.78 USD
4/28/20262.86 USD
4/27/20262.91 USD
4/24/20262.95 USD
4/23/20263.13 USD
4/22/20263.17 USD
4/21/20263.13 USD
4/20/20263.31 USD
4/17/20263.44 USD
4/16/20263.52 USD
4/15/20263.40 USD
4/14/20263.26 USD
4/13/20263.20 USD
4/10/20263.13 USD
4/9/20263.17 USD
4/8/20263.09 USD
4/7/20263.07 USD
4/6/20263.01 USD
4/2/20262.96 USD
4/1/20262.68 USD
3/31/20262.69 USD
3/30/20262.47 USD
3/27/20262.68 USD
3/26/20262.82 USD
3/25/20262.78 USD
3/24/20262.67 USD
3/23/20262.82 USD
3/20/20262.94 USD
3/19/20263.04 USD
3/18/20262.97 USD
3/17/20263.10 USD
3/16/20263.20 USD
3/13/20263.06 USD
3/12/20263.19 USD
3/11/20263.27 USD
3/10/20263.32 USD
3/9/20263.27 USD
3/6/20263.17 USD
3/5/20263.18 USD
3/4/20263.43 USD
3/3/20263.25 USD
3/2/20263.30 USD
2/27/20263.32 USD
2/26/20263.48 USD
2/25/20263.49 USD
2/24/20263.29 USD
2/23/20262.90 USD
2/20/20262.91 USD
2/19/20263.14 USD
2/18/20263.13 USD
2/17/20262.96 USD
2/13/20262.80 USD
2/12/20262.85 USD
2/11/20262.57 USD
2/10/20262.60 USD
2/9/20262.44 USD
2/6/20262.51 USD
2/5/20262.33 USD
2/4/20262.51 USD
2/3/20262.59 USD
2/2/20262.50 USD
1/30/20262.57 USD
1/29/20262.75 USD
1/28/20262.85 USD
1/27/20263.02 USD
1/26/20262.95 USD
1/23/20263.18 USD
1/22/20262.94 USD
1/21/20262.34 USD
1/20/20262.19 USD
1/16/20262.20 USD
1/15/20262.08 USD
1/14/20262.15 USD
1/13/20262.15 USD
1/12/20262.21 USD
1/9/20262.10 USD
1/8/20262.17 USD
1/7/20262.14 USD
1/6/20262.04 USD
1/5/20262.20 USD
1/2/20262.21 USD
12/31/20252.19 USD
12/30/20252.15 USD
12/29/20252.28 USD
12/26/20252.19 USD
12/24/20252.19 USD
12/23/20252.18 USD
12/22/20252.39 USD
12/19/20252.39 USD
12/18/20252.41 USD
12/17/20252.33 USD
12/16/20252.39 USD
12/15/20252.39 USD
12/12/20252.36 USD
12/11/20252.36 USD
12/10/20252.42 USD
12/9/20252.50 USD
12/8/20252.48 USD
12/5/20252.55 USD
12/4/20252.56 USD
12/3/20252.50 USD
12/2/20252.34 USD
12/1/20252.43 USD
11/28/20252.57 USD
11/26/20252.37 USD
11/25/20252.20 USD
11/24/20252.30 USD
11/21/20252.08 USD
11/20/20252.15 USD
11/19/20252.24 USD
11/18/20252.34 USD
11/17/20252.39 USD
11/14/20252.31 USD
11/13/20252.34 USD
11/12/20252.45 USD
11/11/20252.47 USD
11/10/20252.43 USD
11/7/20252.55 USD
11/6/20252.48 USD
11/5/20252.61 USD
11/4/20252.70 USD
11/3/20253.01 USD
10/31/20253.61 USD
10/30/20252.47 USD
10/29/20252.50 USD
10/28/20252.74 USD
10/27/20252.79 USD
10/24/20252.47 USD
10/23/20252.41 USD
10/22/20252.45 USD
10/21/20252.74 USD
10/20/20252.82 USD
10/17/20252.85 USD
10/16/20252.88 USD
10/15/20252.90 USD
10/14/20252.89 USD
10/13/20252.49 USD
10/10/20252.32 USD
10/9/20252.85 USD
10/8/20252.41 USD
10/7/20252.32 USD
10/6/20252.44 USD
10/3/20252.44 USD
10/2/20252.53 USD
10/1/20252.31 USD
9/30/20252.34 USD
9/29/20252.38 USD
9/26/20252.36 USD
9/25/20252.31 USD
9/24/20252.47 USD
9/23/20252.42 USD
9/22/20252.31 USD
9/19/20252.19 USD
9/18/20252.18 USD
9/17/20251.92 USD
9/16/20251.99 USD
9/15/20251.91 USD
9/12/20251.84 USD
9/11/20251.81 USD
9/10/20251.74 USD
9/9/20251.64 USD
9/8/20251.68 USD
9/5/20251.70 USD
9/4/20251.54 USD
9/3/20251.57 USD
9/2/20251.45 USD
8/29/20251.45 USD
8/28/20251.50 USD
8/27/20251.50 USD
8/26/20251.53 USD
8/25/20251.59 USD
8/22/20251.62 USD
8/21/20251.60 USD
8/20/20251.58 USD
8/19/20251.62 USD
8/18/20251.77 USD
8/15/20251.71 USD
8/14/20251.65 USD
8/13/20251.71 USD
8/12/20251.33 USD
8/11/20251.33 USD
8/8/20251.36 USD
8/7/20251.45 USD
8/6/20251.45 USD
8/5/20251.55 USD
8/4/20251.50 USD
8/1/20251.44 USD
7/31/20251.52 USD
7/30/20251.56 USD
7/29/20251.57 USD
7/28/20251.69 USD
7/25/20251.66 USD
7/24/20251.66 USD
7/23/20251.60 USD
7/22/20251.58 USD
7/21/20251.64 USD
7/18/20251.67 USD
7/17/20251.68 USD
7/16/20251.69 USD
7/15/20251.63 USD
7/14/20251.69 USD
Access this data via the Eulerpool API
Get Free API Key

Cabaletta Bio Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
0.00 USD
-54.14 M USD
-52.98 M USD
Jan 1, 2023
0.00 USD
-74.66 M USD
-67.68 M USD
Jan 1, 2024
0.00 USD
-125.14 M USD
-115.86 M USD
Jan 1, 2025 (e)
0.00 USD
-182.27 M USD
-209.21 M USD
Jan 1, 2026 (e)
0.00 USD
-203.24 M USD
-174.28 M USD
Jan 1, 2027 (e)
0.00 USD
-241.19 M USD
-173.82 M USD
Jan 1, 2028 (e)
104.38 M USD
-221.13 M USD
-130.60 M USD
Jan 1, 2029 (e)
444.74 M USD
-26.32 M USD
-31.75 M USD

Cabaletta Bio Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 12, 2026, 9:05 AM
 
REVENUEB USD
REVENUE GROWTH%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201720182019202020212022202320242025e2026e2027e2028e2029e2030e2031e
–––––––––––0.100.440.851.57
––––––––––––326.9291.2284.92
–-12.00-22.00-33.00-46.00-52.00-67.00-115.00-209.00-174.00-173.00-130.00-31.00––
––83.3350.0039.3913.0428.8571.6481.74-16.75-0.57-24.86-76.15––
22.5522.5524.0323.1525.7429.3440.9549.5249.5249.5249.5249.5249.5249.5249.52
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Cabaletta Bio generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Cabaletta Bio retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Cabaletta Bio's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Cabaletta Bio has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Cabaletta Bio's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Cabaletta Bio stock margins

The Cabaletta Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cabaletta Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cabaletta Bio.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
0.00 %
- %
- %
Jan 1, 2021
0.00 %
- %
- %
Jan 1, 2022
0.00 %
- %
- %
Jan 1, 2023
0.00 %
- %
- %
Jan 1, 2024
0.00 %
- %
- %
Jan 1, 2025 (e)
0.00 %
- %
- %
Jan 1, 2026 (e)
0.00 %
- %
- %
Jan 1, 2027 (e)
0.00 %
- %
- %

Cabaletta Bio Stock Revenue, EBIT, Earnings per Share

The Cabaletta Bio earnings per share therefore indicates how much revenue Cabaletta Bio has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.00 USD
-1.46 USD
-1.44 USD
Jan 1, 2021
0.00 USD
-1.80 USD
-1.80 USD
Jan 1, 2022
0.00 USD
-1.85 USD
-1.81 USD
Jan 1, 2023
0.00 USD
-1.82 USD
-1.65 USD
Jan 1, 2024
0.00 USD
-2.53 USD
-2.34 USD
Jan 1, 2025 (e)
0.00 USD
-3.68 USD
-2.17 USD
Jan 1, 2026 (e)
0.00 USD
-4.10 USD
-1.81 USD
Jan 1, 2027 (e)
0.00 USD
-4.87 USD
-1.81 USD

Cabaletta Bio business model & stock analysis

Cabaletta Bio Inc is a biotech company founded in 2017, based in Philadelphia, Pennsylvania. The founders of the company are Michael Milone and Aimee Payne, both renowned experts in immunology. The business model of Cabaletta Bio Inc is to treat rare diseases using T-cell therapies. T-cell therapy is a form of immunotherapy where the patient's own T-cells, which have been taken from their blood, are genetically modified and then reintroduced to the patient. This process is intended to enable the patient's T-cells to recognize and fight specific diseased cells. Cabaletta Bio Inc focuses on developing therapies for rare autoimmune diseases and difficult-to-treat cancers. The company specializes in the development of CAR-T cell therapies (CAR-T stands for Chimeric Antigen Receptor) that enable the patient's T-cells to attack specific tumor or autoimmune cells in the body. Novel CAR-T cell technologies have been developed to allow the T-cells to recognize disease-specific antigens on cell surfaces. This way, the T-cells can selectively target and destroy diseased cells. Cabaletta Bio Inc is working on various areas of T-cell therapy development. The first area involves developing therapies for rare autoimmune diseases such as systemic scleroderma, Juvenile syndrome, or pemphigus vulgaris. The company has initiated clinical trials and collaborates with other research institutions and companies to advance the development of CAR-T cell therapies. Another area of focus for Cabaletta Bio Inc is treating cancers that are difficult to treat and lack therapeutic options, such as leukemia, solid tumors, or sarcomas. Identifying and targeting specific cells for these types of cancers is particularly challenging. Therefore, the company is actively working to develop novel CAR-T cell technologies that enable the T-cells to recognize and combat diseased cells. Currently, Cabaletta Bio Inc does not offer any commercial products as it is still in the phase of clinical research and development. However, the company aims to advance the development of T-cell therapies and make its technology accessible to patients with rare and difficult-to-treat diseases. Overall, Cabaletta Bio Inc has received recognition and support from leading scientists and organizations in recent years. The company has received several awards and accolades for its work, including the New Frontier Award from the National Organization for Rare Disorders (NORD) and the Fast Track Award from the US Food and Drug Administration (FDA). Cabaletta Bio Inc collaborates closely with various research institutions, universities, and companies to improve its technology and develop new therapies. In summary, Cabaletta Bio Inc is an emerging biotech company specializing in the development of T-cell therapies. The company aims to treat rare and difficult-to-treat diseases and make its technology accessible to patients. Although the company currently does not offer commercial products, it has received recognition and support from leading scientists and organizations in recent years and collaborates closely with various research institutions, universities, and companies to improve its technology and develop new therapies.

Cabaletta Bio SWOT Analysis

Strengths

1. Innovative Technology: Cabaletta Bio Inc is equipped with advanced technology that positions them at the forefront of the industry.

2. Strong Intellectual Property: The company holds a robust portfolio of patents and trademarks, providing a solid foundation for their products and services.

3. Expert Team: Cabaletta Bio Inc boasts a highly skilled and experienced workforce, comprising experts in various relevant fields.

Weaknesses

1. Limited Market Presence: The company currently has a relatively small market share, hindering their ability to compete with larger competitors.

2. Dependency on Funding: Cabaletta Bio Inc heavily relies on external funding sources, which may pose challenges in terms of sustainability and financial stability.

3. Lack of Product Diversification: The company's product lineup is currently focused on a specific niche, potentially exposing them to market volatility.

Opportunities

1. Growing Market Demand: The increasing demand for innovative medical solutions presents an opportunity for Cabaletta Bio Inc to expand their customer base.

2. Collaborative Partnerships: Forming strategic alliances with other industry players can enable the company to access new markets and resources.

3. Global Expansion: Cabaletta Bio Inc can explore international markets to capitalize on emerging opportunities and diversify their revenue streams.

Threats

1. Regulatory Challenges: Stringent regulations imposed on the healthcare industry can create hurdles for the company's product development and commercialization.

2. Intense Competition: Cabaletta Bio Inc faces competition from both established companies and emerging startups, putting pressure on their market position.

3. Technological Advancements: Rapid advancements in technology may render the company's existing solutions obsolete if they fail to keep pace with industry trends.

Cabaletta Bio Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Cabaletta Bio historical P/E ratio, EBIT multiple, and P/S ratio

Cabaletta Bio annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Cabaletta Bio shares outstanding

The number of shares of Cabaletta Bio was 49.52 M in 2025. This indicates how many shares Cabaletta Bio is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
23.15 M Stocks
Jan 1, 2021
25.74 M Stocks
Jan 1, 2022
29.34 M Stocks
Jan 1, 2023
40.95 M Stocks
Jan 1, 2024
49.52 M Stocks
Jan 1, 2025 (e)
49.52 M Stocks
Jan 1, 2026 (e)
49.52 M Stocks
Jan 1, 2027 (e)
49.52 M Stocks

Current Cabaletta Bio forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy81.25 % (13)
Hold18.75 % (3)
Sell0.00 % (0)
12M Price Target
14.28
Last Price
2.97
Currency
USD
12M Return Potential
380.00 %
LTM Return
0 %

Cabaletta Bio Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
5/13/2026-0.41USD0.00USD2026 Q1
3/30/2026-0.47USD0.00USD2025 Q4
11/7/2024-0.61USD0.00USD2024 Q3
5/9/2024-0.46USD0.00USD2024 Q1
3/14/2024-0.40USD0.00USD2023 Q4
11/8/2023-0.48USD0.00USD2023 Q3
8/9/2023-0.47USD0.00USD2023 Q2
5/10/2023-0.46USD0.00USD2023 Q1
3/15/2023-0.47USD0.00USD2022 Q4
11/10/2022-0.49USD0.00USD2022 Q3

EESG©

Eulerpool ESG Scorecard© for the Cabaletta Bio stock

34/100
35
Environment
43
Social
23
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Cabaletta Bio shareholder structure

% Name
10.05207%
Bain Capital Life Sciences Investors, LLC
Bain Capital Life Sciences Investors, LLC
9.17187%
Adage Capital Management, L.P.
Adage Capital Management, L.P.
8.82678%
Jennison Associates LLC
Jennison Associates LLC
7.05701%
T. Rowe Price Investment Management, Inc.
T. Rowe Price Investment Management, Inc.
5.19373%
Cormorant Asset Management, LP
Cormorant Asset Management, LP
4.98598%
Alyeska Investment Group, L.P.
Alyeska Investment Group, L.P.
...

Cabaletta Bio Executives and Management Board

SN

Dr. Steven Nichtberger

(63)

Chief Executive Officer, President, Chairman of the Board, Co-Founder · since 2017

Compensation8.10 M USD
DC

Dr. David Chang

(62)

Chief Medical Officer

Compensation3.35 M USD
GB

Dr. Gwendolyn Binder-Scholl

(50)

President - Science and Technology

Compensation3.32 M USD
AM

Mr. Anup Marda

(47)

Chief Financial Officer

Compensation1.53 M USD
SB

Dr. Scott Brun

(57)

Independent Director

Compensation246,810.00 USD

Cabaletta Bio Supply Chain

Cabaletta Bio Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#Name1M3M6M1Y2YTrend
1
Oxford BioMedica
Supplier
0.23
0.79
0.74
0.92
0.38

Frequently asked questions about Cabaletta Bio

The business model of Cabaletta Bio Inc focuses on the development and commercialization of cell therapy products for the treatment of B cell-mediated autoimmune diseases. As a clinical-stage biotechnology company, Cabaletta Bio Inc aims to utilize its proprietary technology platform, the proprietary Chimeric AutoAntibody Receptor (CAAR) T-cell technology, to engineer T cells that can selectively eliminate autoreactive B cells. By targeting the underlying cause of autoimmune diseases, Cabaletta Bio Inc strives to provide potentially curative therapies for patients suffering from diseases such as mucosal pemphigus vulgaris and mucosal pemphigoid.

All fundamentals and in-depth analysis of Cabaletta Bio

Our stock analysis for Cabaletta Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cabaletta Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Cabaletta Bio Stock
Cabaletta Bio Revenue→
Cabaletta Bio Stock
Cabaletta Bio Net Income→
Cabaletta Bio Stock
Cabaletta Bio P/E→
Cabaletta Bio Stock
Cabaletta Bio P/S→
Cabaletta Bio Stock
Cabaletta Bio EBIT→
Cabaletta Bio Stock
Cabaletta Bio Dividend→
Cabaletta Bio Stock
Cabaletta Bio Directors Dealings→
Cabaletta Bio Stock
Cabaletta Bio Stocks→
Cabaletta Bio Stock
Cabaletta Bio Market capitalization→
Cabaletta Bio Stock
Cabaletta Bio Debt→
Cabaletta Bio Stock
Cabaletta Bio Liabilities→
Cabaletta Bio Stock
Cabaletta Bio Equity→
Cabaletta Bio Stock
Cabaletta Bio AAQS→
Cabaletta Bio Stock
Cabaletta Bio Employees→
Cabaletta Bio Stock
Cabaletta Bio ROE→
Cabaletta Bio Stock
Cabaletta Bio ROA→
Cabaletta Bio Stock
Cabaletta Bio ROCE→
Cabaletta Bio Stock
Cabaletta Bio News→
Cabaletta Bio Stock
Cabaletta Bio Analyst Price Targets→

Health Stocks

Cachet Pharmaceutical CoC4 TherapeuticsCadrenal TherapeuticsC&R ResearchCaduceus Software SystemsC.Q. Pharmaceutical Holding CoCaina Technology CoC-Mer Medical HoldingsCalciMedicaC RadCaliber Imaging & DiagnosticsButterfly NetworkAll Stocks A–Z →